D. Scott Ernst - Concepedia

Author

D. Scott Ernst

Also Known As

D Ernst, D S Ernst, D Scott Ernst, D. Ernst, D. S. ERNST, D. S. Ernst, D. Scott Ernst, D. Scott Ernst,, D.S Ernst, D.S. ERNST

104

Publications

5.8K

Citations

H-Index

Concepts

All Affiliations

Princess Margaret Cancer Centre University of Calgary Dana-Farber Cancer Institute Queen Elizabeth II Health Sciences Centre London Health Sciences Centre

About

D. Scott Ernst is an author at Princess Margaret Cancer Centre specializing in medicine, oncology, and urology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	22	30	2.5K
2	Health Sciences	7	7	279
3	Biostatistics	1	1	71
4	Child Development	1	1	17
5	Diagnostic Sciences	1	1	25

D. Scott Ernst

Publications

5.5K

Citations

H-Index

Page 1

	Year	Citations
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. I. F. Tannock, David Osoba, Martin R. Stockler, Journal of Clinical Oncology	1996	1.6K
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Daniel Y.C. Heng, J. Connor Wells, Brian I. Rini, European Urology UrologySurgical OncologyGenitourinary CancerMedicineCytoreductive Nephrectomy	2014	467
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study Jenny J. Ko, Wanling Xie, Nils Kroeger, The Lancet Oncology First-line Targeted TherapyUrologyPopulation-based StudyGenitourinary CancerMedicine	2015	364
Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. Malcolm J. Moore, Ian F. Tannock, D. Scott Ernst, Journal of Clinical Oncology	1997	272
Randomized, Double-Blind, Controlled Trial of Mitoxantrone/Prednisone and Clodronate Versus Mitoxantrone/Prednisone and Placebo in Patients With Hormone-Refractory Prostate Cancer and Pain D. Scott Ernst, I. F. Tannock, Eric Winquist, Journal of Clinical Oncology	2003	248
Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial Nicole Basset‐Séguin, Axel Hauschild, Jean‐Jacques Grob, The Lancet Oncology Open-label TrialMedicinePre-planned Interim AnalysisDermatologyCancer Treatment	2015	242
Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and Prednisone David Osoba, Ian F. Tannock, D. Scott Ernst, Journal of Clinical Oncology	1999	224
Randomized Phase II Study of Two Doses of Gefitinib in Hormone-Refractory Prostate Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group Christina M. Canil, Malcolm J. Moore, Eric Winquist, Journal of Clinical Oncology	2005	207
Prospective trial of cryosurgical ablation of the prostate: five-year results Bryan Donnelly, John C. Saliken, D. Scott Ernst, Urology UrologyBenign Prostatic HyperplasiaSurgeryUrogynecologyProstatic Disease	2002	157
Early-stage squamous cell carcinoma of the oropharynx: Radiotherapy vs. Trans-Oral Robotic Surgery (ORATOR) – study protocol for a randomized phase II trial Anthony C. Nichols, John Yoo, J. Alex Hammond, BMC Cancer Surgical OncologyCancer ManagementSurgeryTrans-oral Robotic SurgeryOral Cancer	2013	140

Page 1